We examined 100 clinically significant isolates of Serratia marcescens for susceptibility to newer cephalosporin and cephamycin antibiotics, alone and in combination with various aminoglycosides. Moxalactam and cefotaxime were the most effective agents; all isolates were inhibited by 25 and 50 ,ug/ml, respectively. All strains were susceptible to amikacin at concentrations safely achievable in serum, whereas gentamicin, netilmicin, and tobramycin inhibited 63, 63, and 16% of the isolates, respectively. Moxalactam, cefotaxime, and amikacin were active against gentamicin-susceptible and gentamicin-resistant strains. Studies of synergy revealed that moxalactam and cefotaxime, in combination with netilmicin or amikacin, were often synergistic and infrequently antagonistic against cephalothin-and gentamicin-resistant strains. These results suggest that moxalactam and cefotaxime, alone or in combination, may be efficacious in treating infections due to multiply antibiotic-resistant S. marcescens.
Over the past decade, Serratia marcescens has achieved preeminence as a cause of serious nosocomial infections (6, 21, 23, 30) . Susceptibility to aminoglycoside antibiotics was, at one time, taken for granted, but the emergence of multiply antibiotic-resistant strains has been a cause for concern (23, 30) .
Cephalosporin antibiotics have been notoriously ineffective against S. marcescens. However, newer generations of cephalosporins, most notably moxalactam (LY127935) and cefotaxime (HR756), have been shown to be extremely active in vitro against both cephalothin-susceptible and cephalothin-resistant strains and some gentamicin-resistant organisms (7, 8, 10, 13, 24, 27) . The potential for synergy has not been extensively evaluated. In the present study, the activity of cephalosporin and other fl-lactam antibiotics, alone and in combination with various aminoglycosides, against S. marcescens was compared. MATERIALS Only strains judged to be involved in clinically significant infections were studied, including: (i) urinary isolates (36 strains) at more than 100,000 organisms per ml of urine on two consecutive daily urine cultures; (ii) wound isolates (21 strains) when S. marcescens was the only organism cultured from an infected area; (iii) sputum isolates (23 strains) when S. marcescens was consistently isolated in pure culture from a patient with purulent sputum, fever, and pulmonary infiltrates; (iv) blood (17 strains); (v) cerebrospinal fluid (2 strains); and (vi) synovial fluid (1 strain Comparative susceptibilities of gentamicinsusceptible and gentamicin-resistant isolates of S. marcescens are shown in Table 2 . The MICs of moxalactam and cefotazime required to inhibit 50 and 90% of gentamicin-susceptible and gentamicin-resistant strains were vitually identical. The MICs of moxalactam and cefotaxime were two-to fourfold higher for gentamicin-resistant isolates when compared with the MICs for gentamicin-susceptible isolates. Cefoxitin and cefamandole were less effective against both groups of isolates, but particularly against the gentamicin-resistant organisms. Gentamicin susceptibility had no effect on the MICs of amikacin, with all strains remaining susceptible to the latter drug. The activity of netilmicin tended to parallel that of gentamicin for both groups of isolates. Tobramycin was, quantitatively, much less active. Most strains were not inhibited by either carbenicillin or ticarcillin.
The effect of inoculum size on the concentrations of moxalactam and cefotaxime required to inhibit 90% of isolates is shown in Table 3 . MICs were twofold higher for both antibiotics at an inoculum of 106 colony-formin; units. Such in- (1, 14, 31) . Gentamicin, netilmicin, and tobramycin were less effective. A total of 84% of the isolates were resistant to tobramycin, a frequency higher than that previously reported (6, 15, 18) .
In general, S. marcescens is resistant to cephalosporins. However, moxalactam and cefotaxime were extremely effective in vitro. The activity of moxalactam against S. marcescens has been evaluated previously (3, 7, 8, 10, 13, 27, 28) .
The MICgo has varied from 0.25 to 16 jig/ml, but, in general, it has been comparable to the MIC90 found in this study. Similar results have been reported for cefotaxime (19, 24) . The effect of increased inoculum size on the activity of older cephalosporin antibiotics has been shown repeatedly. Most recent studies have reported less effect on the activity of moxalactam and cefotaxime, particularly with inocula of s106 colony-forming units per ml (3, 8 (27) . Others have found little difference with both moxalactam and cefotaxime (8, 13) . We found a one-dilution difference with moxalactam when the MIC50 and MlC9o for gentamicin-susceptible and gentamicin-resistant strains were compared, which was comparable to the findings of Hall et al. (13) .
Despite several limitations (20) , tests designed to assess synergism may be necessary to find more effective therapy for multiply antibioticresistant organisms such as S. marcescens. Many combinations of antibiotics have been shown to be synergistic to various degrees (9, 11, 12, 15, 18, 22, 26, 29) . Few studies have evaluated the activities of moxalactam and cefotaxime in combination with other agents against S. marcescens and other bacteria (19) . The combinations of moxalactam and netilmicin or amikacin showed synergistic activity against most cephalothin-and gentamicin-resistant isolates studied, with no antagonism. Netilmicin synergy has been described with other f,-lactam antibiotics (9, 11) and could be due to increased efficacy of netilmicin against S. marcescens, including gentamicin-resistant isolates (5, 17, 25) . Interestingly, this synergistic effect extended to netilmicin-resistant organisms, with a fall in the MIC of netilmicin to levels achievable in serum. Although all isolates were resistant to gentamicin and tobramycin, synergism was demonstrated for some strains. Whereas the MIC of gentamicin in combination was reduced to therapeutic levels, that of tobramycin was not, and both combinations demonstrated frequent antagonism. Thus, these combinations would seem to be less desirable therapeutic alternatives for infections due to S. marcescens.
Moxalactam and cefotaxime are new semisynthetic cephalosporin antibiotics with a wide spectrum of activity (3, 7, 8, 10, 13, 19, 24, 27, 28, 32) . This spectrum includes organisms such as S. marcescens, which are notoriously resistant to older cephalosporins. Moxalactam and, to a lesser extent, cefotaxime are markedly active in vitro against S. marcescens, including gentamicin-resistant isolates (8, 13, 27) . Not previously demonstrated, however, is the fact that moxalactam in combination with netilmicin and amikacin showed synergistic activity against most strains of cephalothin-and gentamicin-resistant S. marcescens and some strains of netilmicinresistant organisms.
